Physician profile
Ariwan Rakvit
NPI 1669424735
$11,121.69
in general payments reported to CMS, 2019-2025
37 companies · $2,528 in 2025
The $2,528 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $253 · 2021: $1,443 · 2022: $1,929 · 2023: $2,173 · 2024: $2,635 · 2025: $2,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,285 · Consulting Fee: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,285.23 |
| Consulting Fee | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,107.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,899.17 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,274.47 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $754.77 | 2019-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $571.42 | 2024-2025 | Vowst, Zenpep |
| Daiichi Sankyo INC. | $487.28 | 2019-2025 | Injectafer |
| Intercept Pharmaceuticals, INC. | $331.81 | 2020-2024 | Ocaliva |
| Qol Medical, LLC | $330.89 | 2022-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $316.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $288.28 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $235.80 | 2022-2024 | Ibsrela |
| Lilly USA, LLC | $164.17 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $154.51 | 2024-2025 | Voquezna |
| Pfizer INC. | $153.82 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $150.99 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $122.79 | 2023 | Imfinzi |
| Gilead Sciences, INC. | $101.45 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $72.40 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $69.41 | 2022-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $58.68 | 2024-2025 | Terlivaz |
| Pentax of America, INC. | $53.31 | 2022 | |
| Celgene Corporation | $52.59 | 2021-2022 | |
| Boston Scientific Corporation | $50.00 | 2023 | |
| Amgen INC. | $40.50 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $39.93 | 2022-2025 | Monoferric |
| Ferring Pharmaceuticals INC. | $38.93 | 2024-2025 | Rebyota |
| Axonics, INC. | $29.93 | 2021 | |
| Redhill Biopharma INC. | $26.08 | 2020 | |
| Genzyme Corporation | $23.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.38 | 2021 | |
| Ucb, INC. | $21.87 | 2020 | |
| Acacia Pharma INC | $18.96 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.53 | 2020 | |
| Organon LLC | $17.93 | 2022 | |
| Allergan, INC. | $12.25 | 2019 | |
| Endogastric Solutions, INC | $7.72 | 2024 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,145.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariwan Rakvit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.